pehub.com -- Adimab Inc., a Lebanon, N.H.-based developer of a human antibody discovery platform in yeast, announced new research collaborations with Pfizer and an undisclosed second company. It also announced the receipt of milestone payments from two prior discovery collaborations with Merck and Roche. No financial details were disclosed. Adimab has raised around $21.5 million in VC funding from Google Ventures, OrbiMed Advisors, Borealis Ventures, Polaris Venture Partners and SV Life Sciences.
